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ABSTRACT 1 
For performance assessment of the lipid-based drug delivery systems (LBDDS), in vitro lipolysis is 2 
commonly applied because traditional dissolution tests do not reflect the complicated in vivo micellar 3 
formation and solubilisation processes. Much of previous research on in vitro lipolysis have mostly 4 
focused on rank-ordering formulations for their predicted performances. In this study, we have 5 
incorporated in vitro lipolysis with microsomal stability to quantitatively predict the oral bioavailability of 6 
a lipophilic antineoplastic drug bexarotene (BEX) administered in LBDDS. Two types of LBDDS were 7 
applied: lipid solution and lipid suspension. The predicted oral bioavailability values (Foral,predicted) of 8 
BEX from linking in vitro lipolysis with microsomal stability for lipid solution and lipid suspension were 9 
34.2  1.6% and 36.2  2.6%, respectively, while the in vivo oral bioavailability (Foral) of BEX was 10 
tested as 31.5  13.4% and 31.4  5.2%, respectively. The Foral,predicted corresponded well with the Foral 11 
for both formulations, demonstrating that the combination of in vitro lipolysis and microsomal stability 12 
can quantitatively predict oral bioavailability of BEX. In vivo intestinal lymphatic uptake was also 13 
assessed for the formulations and resulted in <1% of the dose, which confirmed that liver microsomal 14 
stability was necessary for correct prediction of the bioavailability. 15 
 16 
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 28 
INTRODUCTION 29 
Modern drug discovery programmes have resulted in the development of increased number of drug 30 
candidates with low aqueous solubility 1. It is a general concept that the drug must be solubilised in the 31 
gastrointestinal (GI) tract to be able to access the enterocytes for permeation 2. Poor aqueous solubility 32 
limits the rate of dissolution and consequently the amount of the drug that can be absorbed following 33 
oral administration. In order to overcome such situations, a range of formulation approaches has been 34 
studied including the use of lipids, surfactants, solid dispersions and fabrication of nanoparticles 3. 35 
Among them, the application of lipid-based drug delivery systems (LBDDS), including self-emulsifying 36 
drug delivery system (SEDDS), have been successful in increasing the solubility and oral bioavailability 37 
as well as reducing the variability of oral absorption 2, 4, 5. 38 
 39 
The aim of most LBDDS is to solubilise poorly soluble drugs in the formulation and then maintain the 40 
drug in a solution as it is administered into the GI tract 2. As a result of this solubilisation, the dissolution 41 
step of the drug in the GI tract can be avoided and therefore could promote absorption. For these 42 
reasons, it is a common practice to assess solubility of the drug in various lipids and surfactants during 43 
development of LBDDS 3, 6. It has to be noted however that solubilisation of a drug during formulation 44 
processes does not always lead to solubilised drug under physiological conditions in the GI tract 7. This 45 
is closely related to the complicated processes of LBDDS digestion and mixed micelles formation in the 46 
GI tract 1, 2. Due to this complexity, in vitro lipolysis or digestion systems are recommended to assess 47 
and predict the performance of LBDDS at physiological conditions 8-10. 48 
 49 
Traditionally, studies of performance assessment of LBDDS by in vitro lipolysis mostly provided rank-50 
order of the formulations for further development or achieving certain level of in vitro-in vivo correlations 51 
8, 11-15. Recently, a novel approach of a combined in vitro lipolysis with microsomal metabolism was 52 
developed in our laboratory by Benito-Gallo et al, which provided an opportunity for quantitative 53 
prediction of oral bioavailability of drugs administered in LBDDS 8. However, the concept of in vitro 54 
lipolysis/microsomal metabolism link was developed using only two model compounds, and warrants 55 
validation with additional compounds. In addition, the pharmacokinetic data used to develop the 56 
combined in vitro lipolysis/microsomal metabolism approach was obtained from literature, which was 57 
additional limitation of the previous work 8.  Therefore, in the current study, we show that in vitro lipolysis 58 
linked with microsomal stability can quantitatively predict the oral bioavailability of bexarotene (BEX, 59 
structure shown in Figure 1), an antineoplastic compound, when administered orally in LBDDS in rats. 60 
In addition, the validation of the predictions was achieved in this work by conducting in vivo 61 
bioavailability and intestinal lymphatic transport studies. The information on lymphatic transport is 62 
important as drugs that have substantial intestinal lymphatic transport avoid liver at the first pass, and 63 
therefore hepatic microsomal metabolism element of quantitative prediction could be omitted. 64 
 65 
MATERIALS AND METHODS  66 
Materials 67 
BEX was obtained from LC Laboratories (Woburn, MA, USA). Linoleic acid was purchased from Acros 68 
Organics (Loughborough, UK). Trizma maleate, MgCl2, KH2PO4, K2HPO4, and reduced nicotinamide 69 
adenine dinucleotide phosphate (NADPH), porcine pancreatin powder (8 × USP specifications), sodium 70 
taurocholate (NaTc), NaCl, lecithin, tetrabromo-o-cresol and sunflower oil were from Sigma (Gillingham, 71 
UK). Calcium chloride was from Alfa Aesar (Lancashire, UK). Pooled male rat liver microsome was 72 
purchased from Gibco (Paisley, UK). Polyethylene glycol 400 (PEG400) was obtained from Fisher 73 
Scientific (Loughborough, UK). All solvents used were of HPLC grade or higher. 74 
 75 
Solubility 76 
Aqueous solubility of BEX at different pH was predicted by GastroPlusTM version 9.6.00015 with built-77 
in ADMET PredictorTM v9.0.0.0. Reference solubility at pH 7.0 in water of 50 µM was given as input 16. 78 
Solubility of BEX in various vehicles was measured following a previously reported method with minor 79 
modifications 17. In glass vials, BEX (10 mg) was mixed with 1 mL of PEG400, linoleic acid or sunflower 80 
oil. The mixture was stirred magnetically for 72 h at 37 °C and then was filtered using a Costar Spin-X 81 
Centrifuge Tube (0.22 µm pore size, Fisher Scientific, Loughborough, UK) at 2400 g for 5 min. The 82 
filtrate was collected and subjected for analysis using HPLC-UV. The experiment was conducted in 83 
triplicate. 84 
 85 
In vitro lipolysis 86 
In vitro lipolysis was performed based on the method that was previously validated and reported 8, 18, 19. 87 
The lipolysis digestion buffer was composed of the following: 50 mM tris maleate; 150 mM NaCl; 5 mM 88 
CaCl2, 5 mM NaTc; and 1.25 mM lecithin. The pH was adjusted to 6.8 prior to the experiment. BEX was 89 
formulated using linoleic acid or sunflower oil at 4 mg/mL and was added to the digestion buffer. The 90 
lipolysis was initiated by addition of the enzyme solution prepared from pancreatin extract and the pH 91 
of the reaction mixture was maintained at 6.8 using a pH-stat titrator (T50 Graphix with DG111-SC pH 92 
probe, Mettler Toledo Inc.) and stirred at 37 °C. Following completion of lipolysis, the mixture was 93 
subjected to ultracentrifugation at 268,350 g for 90 minutes at 37 °C (SORVALL® TH-641 Rotor, 94 
Thermo Fisher Scientific, UK). The lipid, micellar and sediment phases were collected and prepared for 95 
analysis using HPLC-UV. After analysis of samples from each phase, the fraction of drug found in each 96 
phase. The concentration of BEX in micellar phase was used to calculate the fraction predicted to be 97 
absorbed (Fabs,predicted) using equations reported previously 8: 98 
𝐹𝑎𝑏𝑠,𝑝𝑟𝑒𝑑𝑖𝑐𝑡𝑒𝑑 = [𝐷𝑟𝑢𝑔]𝑀𝑃 ∙
40 𝑚𝐿
0.3 𝑚𝐿 ∙ 4 𝑚𝑔/𝑚𝐿
 99 
 100 
where, [Drug]MP is the drug concentration (mg/mL) found in micellar phase, 40 mL is the volume of in 101 
vitro lipolysis buffer and 0.3 mL of the 4 mg/mL BEX formulation was used. Experiment was performed 102 
in triplicate. 103 
 104 
Liver microsomal stability 105 
Liver microsomal metabolic stability assay was performed using rat liver microsome following previously 106 
reported methods with minor modifications 8, 20. The reaction mixture was composed of the followings: 107 
0.5 mg microsomal protein per mL; 10 mM MgCl2; 1 mM NADPH; and 84.7 mM potassium phosphate 108 
buffer at pH 7.4. BEX was tested at 1 μM and the reaction was initiated with the addition of NADPH. 109 
Samples were withdrawn at predetermined time points and reaction was terminated by excessive 110 
volume of acetonitrile. Samples were analysed by HPLC-UV and performed in triplicate.  111 
 112 
Half-life (t1/2) of BEX was obtained from the semi-log plot of concentration-time profile: 113 
𝑡1/2 = −
0.693
𝑘
 114 
where, k is the slope obtained by plotting natural log percentage of BEX versus time. The intrinsic 115 
clearance (CLint) was then obtained by the following equation 21, 22: 116 
𝐶𝐿𝑖𝑛𝑡 =
0.693
𝑡1/2
∙
𝑚𝐿 𝑖𝑛𝑐𝑢𝑏𝑎𝑡𝑖𝑜𝑛
𝑚𝑔 𝑚𝑖𝑐𝑟𝑜𝑠𝑜𝑚𝑒𝑠
∙
𝑚𝑔 𝑚𝑖𝑐𝑟𝑜𝑠𝑜𝑚𝑒𝑠
𝑔 𝑙𝑖𝑣𝑒𝑟
∙
𝑔 𝑙𝑖𝑣𝑒𝑟
𝑘𝑔 𝑏𝑜𝑑𝑦 𝑤𝑒𝑖𝑔ℎ𝑡
 117 
where, mg microsomes/g liver and g liver/kg body weight values were 44.8 and 40.0, respectively, for 118 
rats 23. The hepatic clearance (CLh) was then obtained by utilising parallel-tube model 21, 22: 119 
𝐶𝐿ℎ = 𝑄 ∙ (1 − 𝑒
(−
𝐶𝐿𝑖𝑛𝑡
𝑄⁄ )) 120 
 121 
where, Q is hepatic blood flow rate of 55.2 mL/min/kg for rats 23. The fraction that escapes hepatic 122 
metabolism (Fh) was then calculated using the following equation 21, 22: 123 
𝐹ℎ = 1 −  
𝐶𝐿ℎ
𝑄
 124 
The Fh obtained from the above equation also represents the fraction that escapes hepatic first-pass 125 
effect during oral absorption. 126 
 127 
Calculation of predicted oral bioavailability 128 
By incorporating in vitro lipolysis and in vitro metabolic stability results, predicted oral bioavailability 129 
(Foral,predicted) was calculated using the following equation 8: 130 
𝐹𝑜𝑟𝑎𝑙,𝑝𝑟𝑒𝑑𝑖𝑐𝑡𝑒𝑑 = 𝐹𝑎𝑏𝑠,𝑝𝑟𝑒𝑑𝑖𝑐𝑡𝑒𝑑 ∙ 𝐹ℎ 131 
 132 
 133 
Animal experiments 134 
Animals 135 
Procedures and protocols of all animal experiments in this study were approved by the Animal Care 136 
Committee of Sungkyunkwan University (School of Pharmacy) and performed in accordance with 137 
National Institutes of Health guidelines (NIH publication No. 86-23, revised 1985). Male Sprague-138 
Dawley rats (8 weeks of age, body weight 238-274 g) were purchased from Samtako Co. (Osan, 139 
Gyeonggi-do, South Korea). Rats were kept in clean plastic cages with freely accessible standard rat 140 
diet (Samtako Co., Osan, Gyeonggi-do, South Korea) and water. The animals were housed at a 141 
temperature of 22 ± 2 °C with a 12 h light-dark cycle and a relative humidity of 55 ± 10% and were 142 
acclimatised for at least 1 week prior to any procedures. 143 
 144 
In vivo plasma pharmacokinetics 145 
The pharmacokinetics of BEX was characterised in rats after intravenous and oral administrations. Prior 146 
to surgery, the animals were anaesthetised by intraperitoneal injection of Zoletil® 50 (Virbac 147 
Laboratories, Carros, France) (22.5 mg/kg) and cannulated with a polyethylene tubing (0.58 mm i.d., 148 
0.96 mm o.d., Natume, Tokyo, Japan) in the femoral and jugular veins for intravenous administration 149 
group or in the jugular vein only for oral administration group. Following the surgery, animals were kept 150 
in warm, clean cages for recovery for 24 h. For intravenous administration, BEX dissolved in PEG400 151 
was injected into the femoral vein cannula at a dose of 5 mg/kg with injection volume of 1 mL/kg. For 152 
oral administration, BEX formulated in linoleic acid or sunflower oil (4 mg in 1 mL for both formulations) 153 
was administered by oral gavage at a dose of 10 mg/kg with dosing volume of 2.5 mL/kg. Blood samples 154 
(0.1 mL) were collected from the jugular vein cannula at predetermined time points and plasma samples 155 
were harvested by centrifugation at 16000 g for 5 min at 4 °C and stored at -20 °C until analysis. 156 
 157 
In vivo lymphatic uptake 158 
Lymphatic delivery of BEX was characterised in rats after oral administration. Prior to surgery, the 159 
animals were given corn oil (1 mL) by oral gavage to facilitate mesenteric lymph duct cannulation. 160 
Approximately 2 h later, the rats were anaesthetised by intraperitoneal injection of Zoletil® 50 (Virbac 161 
Laboratories, Carros, France) (22.5 mg/kg), and the right side of the flank was shaved by electric clipper 162 
and sterilised by 70% ethanol solution. The mesenteric lymph duct was exposed by incision of the right 163 
abdomen. After punctuation of the duct, a polyethylene tubing (0.58 mm i.d., 0.96 mm o.d., Natume, 164 
Tokyo, Japan) was cannulated. The cannula was fixed and adhered with the use of cyanoacrylate glue. 165 
After cannulation, the wound was closed by suture and surgical clips. The animals were then kept in 166 
warm, clean cages for recovery for 2 h. For oral administration, BEX dissolved in PEG400, linoleic acid 167 
or sunflower oil was administered to three groups of rats by oral gavage at a dose of 10 mg/kg with 2.5 168 
mL/kg dosing volume. The lymph fluid was continuously collected from the cannula and the collection 169 
tube was changed at predetermined intervals. Collected lymph samples were stored at -20 °C until 170 
analysis. 171 
 172 
Analytical methods for determination of concentration levels 173 
Determination of BEX in samples from in vitro experiments 174 
Samples from in vitro experiments were analysed based on a previously reported HPLC-UV method 24 175 
with minor modifications. Modifications included using flow rate of 0.4 mL/min and the use of hexane (3 176 
mL) as the extraction solvent. The range of calibration curves was also adjusted to 500 – 20000 ng/mL. 177 
 178 
Determination of BEX in samples from in vivo experiments 179 
An API 2000 mass spectrometer coupled with a Waters 2690 separation module was used for sample 180 
analysis. Separation was achieved on a Kinetex biphenyl column (100 × 2.1 mm, 2.6 µm, Phenomenex, 181 
Torrance, CA, USA). The column oven temperature was 40 °C and the flow rate was 0.25 mL/min. The 182 
total run time was 8 min and the data were processed by analyst version 1.4.0 (AB Sciex, Framingham, 183 
MA, USA). 184 
 185 
The electrospray ionisation (ESI) source was operated in negative mode. The multiple reaction 186 
monitoring (MRM) parameters and MS/MS conditions were as follows: m/z 347.1  303.4 for BEX; m/z 187 
422.78.9 for tetrabromo-o-cresol (internal standard, IS); curtain gas: 25 psig; collision gas: 5 psig; ion 188 
spray voltage: -4500 V; ion source temperature: 400 °C; ion source gas 1: 20 psig; ion source gas 2: 189 
40 psig; declustering potential: -41 V; focusing potential -350 V; entrance potential: -12 V; collision 190 
energy: -30 eV; collision cell exit potential: -28 eV. 191 
 192 
Both plasma and lymph samples were prepared by protein precipitation with acetonitrile. Samples (50 193 
µL) were added with IS solution (100 µL, 500 ng/mL tetrabromo-o-cresol in acetonitrile) and additional 194 
acetonitrile of 100 µL. The mixture was vortex-mixed for 10 sec and then centrifuged for 5 min at 16000 195 
g. The supernatant (70 µL) was then mixed with 130 µL of water and transferred to a HPLC vial. A 196 
portion (15 µL) of the mixture was injected into the LC-MS/MS. 197 
 198 
 199 
Statistical analyses 200 
All data were presented as mean ± SD (standard deviation). Two-tailed unpaired t-test was applied to 201 
determine statistical significance and a p-value of <0.05 was considered significant. When more than 202 
two groups were compared, a one-way ANOVA followed by Tukey’s multiple comparisons test was 203 
utilised. GraphPad Prism version 7.01 (GraphPad Software, Inc., La Jolla, CA, USA) was used for 204 
statistical analysis. Non-compartmental analysis using Phoenix WinNonlin 6.3 software (Pharsight, 205 
Mountain View, CA, USA) was applied to calculate the pharmacokinetic parameters from plasma 206 
concentration-time profiles. 207 
 208 
 209 
RESULTS 210 
The predicted pH-dependent aqueous solubility profile of BEX is shown in Figure 1. Although it was 211 
predicted to be slightly higher in basic pH conditions, the solubility in overall was predicted to be <0.1 212 
mg/mL. It was in agreement with the fact that BEX is a class II drug of the Biopharmaceutics 213 
Classification System (BCS) and therefore BEX would benefit with application of LBDDS 16, 25. 214 
 215 
Solubility assessment results of BEX in linoleic acid and sunflower oil are shown in Figure 2. The 216 
solubility of BEX in linoleic acid was 6.2-fold higher than in sunflower oil. It should be noted that the 217 
solubility in sunflower oil was <4 mg/mL, and hence the formulation of BEX in sunflower oil used for in 218 
vitro lipolysis and in vivo pharmacokinetic experiments was a lipid suspension. Solubility of BEX in 219 
linoleic acid was >4 mg/mL and therefore the formulation tested in the experiment was a clear solution. 220 
 221 
Both formulations of BEX in linoleic acid and sunflower oil were tested for their performance in in vitro 222 
lipolysis system (Figure 3). Interestingly, both formulations resulted in comparable fractions of the drug 223 
found in the micellar phase, although formulation of linoleic acid was a clear solution and that of 224 
sunflower oil was a suspension. It showed that the concentration of BEX in the micellar phase is 225 
comparable regardless of their solubilised state in the formulation.  226 
 227 
The results of liver microsomal stability of BEX performed using rat liver microsome is shown in Table 228 
1. The parameters of CLint, CLh and Fh were calculated from the half-life obtained from the stability test 229 
and the obtained Fh indicated that BEX would be classified as a moderately extracted compound 26. 230 
 231 
In vivo plasma pharmacokinetic profiles were determined in rats following intravenous and oral 232 
administrations. The profiles are shown in Figure 4 and pharmacokinetic parameters derived from the 233 
profiles are shown in Table 2. Although the Cmax differed between the two formulations following oral 234 
administration, the overall exposure, determined by AUCinf, did not differ significantly. Therefore, the 235 
oral bioavailability (Foral) was comparable between the two formulations. The elimination half-life was 236 
also not significantly different between the formulations. 237 
 238 
Following the method of the previously reported study 8, two predicted values were obtained: the fraction 239 
predicted to be absorbed (Fabs,predicted) and the predicted oral bioavailability (Foral,predicted). The Foral,predicted, 240 
which incorporates results of in vitro lipolysis and liver microsomal stability, resulted in comparable 241 
values to the in vivo experimental Foral values (Table 2). It demonstrated that oral bioavailability of BEX 242 
achievable by LBDDS can be quantitatively predicted by application of in vitro lipolysis linked with 243 
microsomal stability.  244 
 245 
 246 
The intestinal lymphatic transport of BEX resulting from the formulations was tested with mesenteric 247 
lymph duct cannulated rats (Figure 5). For this purpose, a lipid-free vehicle (PEG400) was also tested 248 
and it was shown that both formulations did not improve lymphatic uptake of BEX compared with the 249 
lipid-free vehicle. 250 
 251 
 252 
DISCUSSION 253 
In vitro lipolysis experiments are commonly utilised in assessment of LBDDS because the performance 254 
of LBDDS can be complicated by physiological processes of lipid digestion and therefore simple 255 
dissolution tests are often not applicable 1, 27. In general, in the in vitro lipolysis studies, the amount of 256 
the drug in the micellar fraction is considered to have the most relevance to oral absorption 8. This is 257 
because the micellar phase consists of mixed micelles with the solubilised drug which represents the 258 
fraction readily available for absorption. The lipid fraction contains the undigested lipids and the 259 
sediment fraction is what has precipitated during the lipolysis, therefore the drug in these two fractions 260 
is not readily available for absorption. Both formulations of linoleic acid and sunflower oil resulted in 261 
comparable fraction of BEX in the micellar phase following lipolysis (Figure 3), and therefore were 262 
predicted to have comparable fraction absorbed (Fabs,predicted, Table 2). These results indicate that the 263 
performance of the two formulations following oral administration would be at similar levels. 264 
 265 
The Fabs,predicted was then incorporated with Fh values from microsomal stability tests to predict oral 266 
bioavailability (Foral,predicted), hence reflecting both absorption and hepatic first-pass effect. The Foral,predicted 267 
values for the two formulations shown in Table 2 corresponded to the Foral values obtained from in vivo 268 
pharmacokinetic experiments, which demonstrates that the approach of linking in vitro lipolysis with 269 
microsomal stability can quantitatively predict the oral bioavailability of BEX following its administration 270 
in LBDDS.  271 
 272 
The quantitative prediction of oral bioavailability was shown to be successful for two types of LBDDS in 273 
this study: lipid suspension (sunflower oil) and lipid solution (linoleic acid) (Table 2). Although sunflower 274 
oil was not able to fully solubilise BEX at 4 mg/mL, it interestingly resulted in comparable performance 275 
in in vitro lipolysis with linoleic acid formulation in which BEX was fully solubilised (Figure 3). Moreover, 276 
it was remarkable that the two formulations resulted in comparable in vivo Foral (Table 2), although a 277 
suspension would have had an additional dissolution step included in the solubilisation processes of 278 
the drug. This highlights the fact that the in vitro lipolysis offers a more biorelevant performance 279 
assessment of LBDDS than traditional dissolution and that the in vitro lipolysis/microsomal metabolism 280 
link approach can be applied to different types of LBDDS. 281 
 282 
Although in vitro lipolysis has been mainly used for digestible lipids, as the experimental system 283 
contains lipase enzyme, we here show that it can also be applied to formulations of lipid-digestion 284 
product (or indigestible lipid). Linoleic acid used in this study is a free fatty acid which is in fact one of 285 
the products of lipid digestion and the applicability of in vitro lipolysis is demonstrated by the Foral,predicted 286 
corresponding with the experimental in vivo Foral (Table 2). The presence of lipids or digestive products, 287 
including free fatty acids, in the GI tract itself can induce release of the cholecystokinin, which stimulates 288 
secretion of pancreatic enzymes and bile acids 2, 28. The in vitro lipolysis system mimics these 289 
endogenous components and therefore it better mimics the environment of the GI tract. Although 290 
indigestible lipids and lipid-digestion products would not benefit from the ‘lipolysis’ process, the in vitro 291 
lipolysis system as a whole provides more biorelevance in assessment of their ability to facilitate mixed 292 
micelle formation and hence drug solubilisation. 293 
 294 
 295 
It should be noted that BEX has logP of 7.28 (ACD/Labs, Toronto, Canada) and belongs to class II of 296 
the BCS 25. Accordingly, the oral bioavailability of BEX would be more dependent on solubility in the GI 297 
tract rather than permeability across membranes. Therefore in vitro lipolysis results were sufficient to 298 
predict the absorbed fraction without consideration of permeability which was in accordance with 299 
previous studies for similar compounds 8, 12, 13.  300 
 301 
The results in Figure 5 show that the intestinal lymphatic uptake did not differ significantly between the 302 
two formulations, and in fact not different from a lipid-free vehicle. LBDDS are often employed to 303 
enhance intestinal lymphatic delivery of lipophilic drugs for the purpose of increasing the oral 304 
bioavailability and/or targeting the intestinal lymphatic system 3, 28-30. It has been previously suggested 305 
that it is the inherent physicochemical properties of the drug that determines the association ability of 306 
the drug with chylomicrons which eventually governs intestinal lymphatic transport 17, 31. The intestinal 307 
lymphatic transport of BEX, with its low chylomicron association reported previously 32, was not affected 308 
by LBDDS. It confirms the relevance of application of liver microsomal stability in bioavailability 309 
prediction as minimal lymphatic transport would mean that hepatic first-pass effect would be applied to 310 
BEX 8. When hepatic first-pass effect is applied to the absorbed drug, in vitro lipolysis system alone 311 
would not be able to predict the oral bioavailability accurately. Therefore, it becomes evident that liver 312 
microsomal stability studies needed to be linked with in vitro lipolysis in order to quantitatively predict 313 
the oral bioavailability of BEX.  314 
 315 
In conclusion, we have shown that oral bioavailability of LBDDS can be quantitatively predicted by 316 
incorporation of in vitro lipolysis and microsomal stability. The evaluations and predictions were applied 317 
to formulations of a lipid suspension and a lipid solution, which resulted in comparable in vitro and in 318 
vivo performance. The predictability of the approach was found to be acceptable for the two different 319 
types of LBDDS. In order to make a head-to-head comparison, experimental bioavailability obtained 320 
from our own in vivo pharmacokinetic studies was used. Additionally, intestinal lymphatic transport was 321 
assessed for the formulations to confirm that microsomal stability results need to be linked with in vitro 322 
lipolysis for the oral bioavailability prediction.  323 
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 443 
 444 
FIGURE CAPTIONS 445 
 446 
Figure 1. Chemical structure of bexarotene (A) and pH-dependent solubility predicted by 447 
GastroPlusTM (B). 448 
 449 
Figure 2. Solubility assessment of bexarotene in linoleic acid and sunflower oil (mean ± SD, n = 3). **, 450 
p<0.05. 451 
 452 
Figure 3. In vitro lipolysis assessment of bexarotene in formulations of linoleic acid (solution) and 453 
sunflower oil (suspension). The amount of drug was analysed in lipid, micellar and sediment phases 454 
(mean ± SD, n = 3). N/S, not significant. 455 
 456 
Figure 4. Plasma concentration-time profiles of BEX following intravenous administration at 5 mg/kg 457 
(in PEG400) and oral administration at 10 mg/kg (in linoleic acid or sunflower oil) in rats (mean ± SD, n 458 
= 5). 459 
 460 
Figure 5. Cumulative intestinal lymphatic uptake of BEX from different formulations in 24 h following 461 
oral administration in mesenteric lymph duct cannulated rats (mean ± SD, n = 3). N/S, not significant. 462 
 463 
 464 
